A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia
Phase of Trial: Phase III
Latest Information Update: 09 May 2018
At a glance
- Drugs Alirocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms ODYSSEY HoFH
- Sponsors Regeneron Pharmaceuticals
- 02 May 2018 Planned End Date changed from 1 Apr 2019 to 18 Jun 2019.
- 02 May 2018 Planned primary completion date changed from 1 Dec 2018 to 23 Jan 2019.
- 08 Nov 2017 According to Regeneron Pharmaceuticals media release, this trial was initiated in the third quarter of 2017.